Pharmacology of antiplatelet agents.

Abstract

Pharmacotherapies with agents that inhibit platelet function have proven to be effective in the treatment of acute coronary syndromes, and in the prevention of complications during and after percutaneous coronary intervention. Because of multiple synergetic pathways of platelet activation and their close interplay with coagulation, current treatment strategies are based not only on platelet inhibition, but also on the attenuation of procoagulant activity, inhibition of thrombin generation, and enhancement of clot dissolution. Current strategies can be broadly categorized as anticoagulants, antiplatelet agents, and fibrinolytics. This review focuses on the pharmacology of current antiplatelet therapy primarily targeting the inhibition of the enzyme cyclooxygenase 1, the P2Y12 receptor, the glycoprotein IIb/IIIa receptor, and protease-activated receptor 1.

• Authors: Kiran Kalra, Christopher J Franzese, Martin G Gesheff, Eli I Lev, Shachi Pandya, Kevin P Bliden, Udaya S Tantry, Paul A Gurbel
• Journal: Current atherosclerosis reports (Curr Atheroscler Rep) Vol. 15 Issue 12 Pg. 371 (Dec 2013) ISSN: 1534-6242 [Electronic] United States
• PMID: 24142550 (Publication Type: Journal Article, Review)

Chemical References

• Anticoagulants
• Platelet Aggregation Inhibitors

Topics

• Acute Coronary Syndrome (drug therapy)
• Animals
• Anticoagulants (pharmacology)
• Blood Coagulation (drug effects)
• Contraindications
• Humans
• Platelet Activation (drug effects)
• Platelet Aggregation Inhibitors (pharmacology)